Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

J. Burstein, Harold; Keshaviah, Aparna; David Baron, Ari; D. Hart, Ronald; Lambert-Falls, R.; Kelly Marcom, P.; Gelman, Rebecca; P. Winer, Eric

doi:10.1002/cncr.22885

Public

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Published in Cancer • Jul 5, 2007

Authors:

Harold J. Burstein

Aparna Keshaviah

Ari David Baron

Abstract

BACKGROUND: The optimal trastuzumab-based chemotherapy regimen for HER2-overexpressing, metastatic breast cancer is not known. The trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare these regimens. METHODS: Eligible pa...

Subject

Vinorelbine

Taxane

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!